Itxarone Bilbao Aguirre *

Autor invitado por SIIC

El trabajo contribuye a la controversia de la retirada de los regímenes inmunosupresores basados en anticalcineurínicos en receptores de trasplante hepático estables con reacciojnes adversas a los anticalcineurínicos

INMUNOSUPRESION BASADA EN MOFETIL MICOFENOLATO EN RECEPTORES DE TRASPLANTE HEPÁTICO ESTABLES

En receptores de trasplante hepático estables con insuficiencia renal crónica u otros efectos adversos secundarios al uso crónico de anticalcineurínicos (ACN) recomendamos cambiar pronto la pauta inmunosupresora. La conversión a pautas dobles basadas en mofetil micofenolato (MMF) y dosis bajas de ACN sería el primer paso a realizar. Si el efecto adverso persiste, la supresión total y progresiva del ACN y la utilización de MMF en monoterapia sería el segundo paso. La supresión total de los ACN obliga a una monitorización muy estricta de los pacientes, ya que el riesgo de rechazo tardío es muy alto si consideramos que son pacientes estables.

*Itxarone Bilbao Aguirre
describe para SIIC los aspectos relevantes de su trabajo
IMMUNOSUPPRESSION BASED ON MYCOPHENOLATE MOFETIL IN STABLE LIVER TRANSPLANTED PATIENTS
Institución principal de la investigación
*Hospital Vall D'Hebron, Barcelona, España
Imprimir nota

Referencias bibliográficas
1. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy and risk of development and treatment. Transplantation 72(12):1934-9, 2001.
2. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplantation Reviews 14(2):65-81, 2000.
3. Ojo AO, Held PJ, Port FK, Wolfe RA,Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349(10):931-40, 2003.
4. Paramesh AS, Roayale S, Doan Y, Schwartz ME, Emre S, Fishbein T, Floman S, Gondolesi GE, Krieger N, Ames S, Bromberg JS and Akalin E. Post-liver transplant acute renal failure : factors predicting development of end-stage renal disease. Clinical Transplantation 18:94, 2004.
5. Tesis doctoral Cristina Dopazo (Directora de tesis I. Bilbao). www.mcu.es/teseo/Ref 53111679XD.
6. Lipsky JL. Mycophenolate mofetil. Lancet 348:1357, 1996.
7. Finzi D, Siciliano RF. Taking aim at HIV replication. Nat Med 6:735-736, 2000.
8. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monitoring 22.27-30, 2000.
9. Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J, Venkataramanan R. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 45(1):34-41, 2005.
10. Schlitt HJ, Barkmann A, Böker KK, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 357:587-591, 2001.
11. Koch RO, Graziadei IW, Schutz F, Nachbaur K, Königsrainer A, Margreiter R, Vogel W. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transplant International 2004.
12. Pageaux GP, Rostaig L, Calmus Y, Duvoux C, Vanlemmeus C, Hardgwissen J, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 12(12):1755-60, 2006.
13. Orlando G, Baiocchi L, Cardillo A, Iaria G, De Lignori N, Tisonne G, et al. Switch to 1,5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipemia, and hypertension. Liver Transpl 13(1):46-54, 2007.
14. Reich DJ, Clavien PA, Hodge EE. MMF renal dysfunction after liver transplantation working group. Transplantation 80(1):18-25, 2005.
15. Hong MK, Angus PW, Jones RM, Vaughan RB, Gow PJ. Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction. Clin Transplant 19(2):193-8, 2005.
16. Steward SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 357(9256):609-10, 2001.

Otros artículos de Itxarone Bilbao Aguirre

Castells L, Escartin A, Bilbao I, et al. Liver transplantation in HIV-HCV coinfected patients in a cse-control study. Transplantation 83(3):354-8, 2007.
Castells L, Esteban JI, Bilbao I et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther 11(8):1061-70, 2006.
Martínez Llordella M, Puig Pey I, Orlando G, Ramoni M, Tisone G, Rimola A, Lerut J, Bilbao I, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transpl 7(2):309-19, 2007.
Ocaña L, Cos J, Quer J, Bilbao I et al. Analysis of IFN-gamma, TNF-alpha and dendritic cells to predict hepatitis C recurrence in liver transplanted patients. Transpl Proc 37(9):3951-6, 2005.
Margarit C, Bilbao I, Castells L, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 18(12):1336-45, 2005.
Castells L, Vargas V, Allende H, Bilbao et al. Combined treatment with pegylated interferon (alpha 2b) and ribavirine in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 43(1):53-9, 2005.
Bilbao I, Armadans L, Lazaro JL, et al. Predictive factors for early mortality following liver transplantation. Clin Tranplantation 17(5):401-11, 2003.
Charco R, Bilbao I, Chávez R, et al. Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression. Transpl Proc 34(5):1555-6 9, 2002.
Charco R, Cantarell C, Castells L, Bilbao I et al. Changes in renal function in long-term survivors of liver transplantation : a comparison between cyclosporine microemulsion and tacrolimus therapy. Transpl Proc 34(5):1548-9, 2002.
Cos J, Villalba T, Parra R, Gallardo D, Bilbao I, et al. FK 506 in the maturation of dendritic cells. Haematologica 87(7):679-87, 2002.
Bilbao I, Pou L, Allende E et al. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. Transpl Proc 33(3):2124-6, 2001.
Margarit C, Bilbao I, Charco R, et al. Auxiliary heterotopic liver transplantation with portal vein arterialization for fulminant hepatic failure. Liver Transpl 6(6):805-9, 2000.
Pou L, Brunet M, Bilbao I, et al. Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK 506 multicenter Spanish Study Group: a two-year follow-up. Ther Drug Monit 20(6):602-6, 1998.
Bilbao I, Parrilla P, Rimola A, et al. Improvement in correlation between oral dose of cyclosporine and cyclosporinemia after substitution of conventional cyclosporine by Neoral cyclosporine in 296 liver transplant patients. Transpl Proc 30(5):1833-7, 1998.
Bilbao I, Lázaro JL, Pou L, et al. Experience with neoral cyclosporine through the oral route in liver transplantation. Transpl Proc 30(4):1432-4, 1998.
Bilbao I, Charco R, Balsells J, et al. Risk factor for acute renal failure requiring dialysis after liver transplantation. Clin Tranplantation 12(2):123-9, 1998.

Para comunicarse con Itxarone Bilbao Aguirre mencionar a SIIC como referencia:
ibilbao@vhebron.net

---

Acerca del trabajo completo

INMUNOSUPRESION BASADA EN MOFETIL MICOFENOLATO EN RECEPTORES DE TRASPLANTE HEPÁTICO ESTABLES

Título original en castellano
Inmunosupresion basada en Mofetil Micofenolato en pacientes trasplantados hepAticos estables

Autor
Itxarone Bilbao Aguirre¹, Luis Castells², Luis Rojas³, Jorge Cancino⁴, Cristina Dopazo⁵, Ernesto Castro⁶, Leonor Pou⁷, Carlos Margarit⁸
1 Médico (Cirujana), Hospital Vall D'Hebron, Barcelona, España, Cirujano Adjunto
2 Médico Internista, Hospital Vall D?Hebron, Barcelona, España, Médico Adjunto
3 Médico Cirujano
4 Médico Cirujano
5 Médico Cirujano
6 Médico Cirujano
7 Bioquímica
8 Médico Cirujano, Hospital Vall D?Hebron, Barcelona, España, Jefe Unidad de Trasplante Hepático

Acceso a la fuente original
International Immunopharmacology
http://www.sciencedirect.com/science/journal/15675769